Traduction de «other risk » (Néerlandais → Français) :

TERMINOLOGIE

controle van zwangerschap met verhoogd risico [high-risk]
Surveillance d'une grossesse à haut risque

TRADUCTIONS EN CONTEXTE

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Risk factors that cannot be changed (such as a previous attempted suicide) can alert others to the heightened risk of suicide during periods of the recurrence of a mental or substance abuse disorder following a particularly stressful life event (Oquendo et al., 1999).
Les facteurs de risque qui ne peuvent pas être changés (comme les tentatives de suicide antérieures) peuvent alerter les autres du risque accru de suicide durant des périodes de récurrence de troubles mentaux ou d’abus de substances à la suite d’un événement de vie particulièrement stressant (Oquendo et al., 1999).

However, the Council remains concerned that these energy drinks increase the risk of excessive and potentially harmful caffeine consumption and its consequences (such as insomnia, nervousness, anxiety, headaches, trembling and tachycardia), as well as the risk of potentially inducing an addiction to caffeine and, as has been noted more recently, a dependence on other substances (nicotine, alcohol and/or cannabis).
Il reste néanmoins préoccupé par le risque accru d’une surconsommation potentiellement nuisible de caféine et des conséquences que celle-ci implique telles que insomnie, nervosité, anxiété, maux de tête, tremblements et tachycardie, mais également, la possibilité d’induction d’une dépendance à la caféine ou à d’autres substances (nicotine, alcool et/ou cannabis), plus récemment évoquée.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases. Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.
Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.

This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.
This information contained in this release is as of June 2, 2011, Pfizer assumes no obligation to update forward-looking statements contaiTned in this release as the result of new information or future events or developments. This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.

Depending on the age group, other specific risk and protective factors can be significant.
Selon les groupes d’âge, d’autres facteurs de risque et de protection spécifiques peuvent être significatifs.

Moreover, relapses into depression and co-morbidity with other disorders, such as anxiety, increase the risk of suicide (Angst et al., 1999).
En outre, les rechutes de dépression et la comorbidité avec d’autres troubles comme l’anxiété augmentent le risque de suicide (Angst et al., 1999).

Ingesting toxic substances, alcohol or other, whilst suffering from a DSM-IV axis I or II pathology, can constitute an important risk factor, regardless of whether this happens occasionally or as a result of regular abuse or dependence.
La prise de toxiques, alcool ou autre, qu’elle soit occasionnelle ou organisée en abus ou dépendance, en résonance avec une pathologie de l’axe I ou de l’axe II du DSM-IV, peut constituer un facteur de risque important.